AVITA Medical Inc

RCEL remains in a sustained Stage 4 decline with persistent lower highs and lower lows and price below all key moving averages. Oversold conditions at current levels increase the risk of a bounce, so under the speculative strategy we defer selling to rallies into resistance around the EMAs to ensure asymmetric entry.

• ↑Q2 revenue of $21.7M grew 18% YoY driven by RECELL sales.
• ↑Full-year 2026 revenue guidance boosted to $86–89M with Q4 cash-flow breakeven forecast.
• ↓Negative earnings yield and weak book-to-price suggest rich valuation.